{"sent_idx": "7", "frame_idx": "0", "ev": "For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), \u221211.1 versus \u22126.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).", "icos": [["0.9801073", "placebo", "subcutaneous BMT", "sexual function index"], ["0.97747666", "placebo", "BMT", "sexual function index"], ["0.9754625", "placebo", "placebo - controlled", "sexual function index"], ["0.96799636", "placebo", "bremelanotide ( BMT ),", "sexual function index"], ["0.9668247", "placebo", "testosterone", "sexual function index"]], "sample": "c"}
{"sent_idx": "7", "frame_idx": "1", "ev": "For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), \u221211.1 versus \u22126.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).", "icos": [["0.9823016", "placebo", "subcutaneous BMT", "sexual distress scale - desire / arousal / orgasm total score"], ["0.9808024", "placebo", "BMT", "sexual distress scale - desire / arousal / orgasm total score"], ["0.9806676", "placebo", "placebo - controlled", "sexual distress scale - desire / arousal / orgasm total score"], ["0.97576684", "placebo", "Bremelanotide ( BMT )", "sexual distress scale - desire / arousal / orgasm total score"], ["0.97528005", "placebo", "Placebo -", "sexual distress scale - desire / arousal / orgasm total score"]], "sample": "c"}
{"sent_idx": "104", "frame_idx": "2", "ev": "In the mITT population, the mean (SD) change in number of SSEs from baseline to EOS was +0.7 (2.4) events/month for BMT 1.25/1.75 mg pooled, compared with +0.2 (2.3) for placebo (p = 0.0180).", "icos": [["0.99658895", "placebo", "subcutaneous BMT", "mean ( SD ) change in number of SSEs"], ["0.9957403", "placebo", "intranasal BMT formulation", "mean ( SD ) change in number of SSEs"], ["0.99330574", "placebo", "BMT", "mean ( SD ) change in number of SSEs"], ["0.99329054", "placebo", "BMT or matching placebo", "mean ( SD ) change in number of SSEs"], ["0.9908031", "placebo", "placebo or BMT", "mean ( SD ) change in number of SSEs"]], "sample": "c"}
{"sent_idx": "111", "frame_idx": "9", "ev": "However, statistically significant improvement versus placebo was identified at 1.25/1.75 mg for total score and for desire score on both the FSDS-DAO and the FSFI, and at 1.75 mg for all FSDS-DAO and FSFI outcomes.", "icos": [["0.9806388", "placebo", "intranasal BMT formulation", "desire score"], ["0.97620547", "placebo", "BMT or matching placebo", "desire score"], ["0.97421175", "placebo", "BMT", "desire score"], ["0.97341806", "placebo", "placebo or BMT", "desire score"], ["0.9718787", "placebo", "placebo - controlled", "desire score"]], "sample": "c"}
{"sent_idx": "111", "frame_idx": "10", "ev": "However, statistically significant improvement versus placebo was identified at 1.25/1.75 mg for total score and for desire score on both the FSDS-DAO and the FSFI, and at 1.75 mg for all FSDS-DAO and FSFI outcomes.", "icos": [["0.97508174", "placebo", "subcutaneous BMT", "total score"], ["0.97499824", "placebo", "intranasal BMT formulation", "total score"], ["0.97354907", "placebo", "BMT", "total score"], ["0.9732694", "placebo", "BMT or matching placebo", "total score"], ["0.9707701", "placebo", "placebo - controlled", "total score"]], "sample": "c"}
{"sent_idx": "137", "frame_idx": "11", "ev": "Seventy BMT users (24% of 297) and seven placebo users (7% of 97) reported injection-site reactions, defined as encompassing irritation, rash, urticaria, swelling, pruritus, warmth, erythema, hematoma, hemorrhage, induration, nodule or pain.", "icos": [["0.9992005", "placebo", "BMT", "injection - site reactions"], ["0.9989801", "placebo", "subcutaneous BMT", "injection - site reactions"], ["0.9979657", "placebo", "intranasal BMT formulation", "injection - site reactions"], ["0.9961427", "placebo", "Bremelanotide ( BMT )", "injection - site reactions"], ["0.995952", "placebo", "placebo or BMT", "injection - site reactions"]], "sample": "c"}
{"sent_idx": "137", "frame_idx": "12", "ev": "Seventy BMT users (24% of 297) and seven placebo users (7% of 97) reported injection-site reactions, defined as encompassing irritation, rash, urticaria, swelling, pruritus, warmth, erythema, hematoma, hemorrhage, induration, nodule or pain.", "icos": [["0.999305", "placebo", "subcutaneous BMT", "irritation , rash , urticaria , swelling , pruritus , warmth , erythema , hematoma , hemorrhage , induration , nodule or pain ."], ["0.999065", "placebo", "BMT", "irritation , rash , urticaria , swelling , pruritus , warmth , erythema , hematoma , hemorrhage , induration , nodule or pain ."], ["0.9908047", "placebo", "intranasal BMT formulation", "irritation , rash , urticaria , swelling , pruritus , warmth , erythema , hematoma , hemorrhage , induration , nodule or pain ."], ["0.98701686", "placebo", "placebo - controlled", "irritation , rash , urticaria , swelling , pruritus , warmth , erythema , hematoma , hemorrhage , induration , nodule or pain ."], ["0.9862574", "placebo", "placebo or BMT", "irritation , rash , urticaria , swelling , pruritus , warmth , erythema , hematoma , hemorrhage , induration , nodule or pain ."]], "sample": "c"}
